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Abstract
Inherited and de novo genomic imbalances at chromosome 16p11.2 are associated with autism spectrum disorders (ASD),
but the causative genes remain unknown. Among the genes located in this region, PRRT2 codes for a member of the
synaptic SNARE complex that allows the release of synaptic vesicles. PRRT2 is a candidate gene for ASD since homozygote
mutations are associated with intellectual disability and heterozygote mutations cause benign infantile seizures, paroxysmal
dyskinesia, or hemiplegic migraine. Here, we explored the contribution of PRRT2 mutations in ASD by screening its coding
part in a large sample of 1578 individuals including 431 individuals with ASD, 186 controls and 961 individuals from the
human genome Diversity Panel. We detected 24 nonsynonymous variants, 1 frameshift (A217PfsX8) and 1 in-frame deletion
of 6 bp (p.A361_P362del). The frameshift mutation was observed in a control with no history of neurological or psychiatric
disorders. The p.A361_P362del was observed in two individuals with autism from sub-Saharan African origin. Overall, the
frequency of PRRT2 deleterious variants was not different between individuals with ASD and controls. Remarkably, PRRT2
displays a highly significant excess of nonsynonymous (pN) vs synonymous (pS) mutations in Asia (pN/pS = 4.85) and Europe
(pN/pS = 1.62) compared with Africa (pN/pS = 0.26; Asia vs Africa: P = 0.000087; Europe vs Africa P = 0.00035; Europe vs Asia
P = P= 0.084). We also showed that whole genome amplification performed through rolling cycle amplification could
artificially introduce the A217PfsX8 mutation indicating that this technology should not be performed prior to PRRT2
mutation screening. In summary, our results do not support a role for PRRT2 coding sequence variants in ASD, but provide
an ascertainment of its genetic variability in worldwide populations that should help researchers and clinicians to better
investigate the role of PRRT2 in human diseases.
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Introduction
Autism Spectrum Disorders (ASD) are characterized by
impairments in reciprocal social communication, and repetitive,
stereotyped and ritualistic behaviors [1]. ASD include autism,
Asperger syndrome and pervasive developmental disorder not
otherwise specified (PDD-NOS). The prevalence of ASD overall is
about 1/100, but closer to 1/300 for autism with intellectual
disability (ID) [2]. The susceptibility genes to ASD remain largely
unknown, but mutations affecting genes such as NLGN3/4X,
SHANK2/3, NRXN1 and CNTNAP2 were shown to alter synaptic
function and increase the risk for ASD [3]. Several large-scale
studies have reported an enrichment of copy number variants
(CNVs) in individuals with ASD [4,5], suggesting that gene dosage
plays a key role in the susceptibility to ASD [6]. Among the
recurrent genomic alterations associated with ASD, de novo or
inherited submicroscopic microdeletion/duplication at 16p11.2
have been associated with a variety of developmental/neuropsy-
chiatric disorders including ASD, intellectual disability (ID),
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schizophrenia, or bipolar disorders, but also with body mass index
[7–14]. A meta-analysis of 6 studies including more than 2000
individuals and 30000 controls provided strong support for the
role of recurrent 16p11.2 genomic imbalances as risk factors for
ASD (duplication OR:20.7 and P= 1.961027; deletion OR:38.7
and 2.3610213) [13]. The deleted/duplicated region at 16p11.2
spans 500–600 kb and is flanked by large and highly similar
147 kb low copy repeats with .99% homology, predisposing to
unequal crossing-over during meiosis [10–14]. Among the 27
genes located within the interval, Kumar et al. (2009) screened for
rare variations in 8 candidate genes selected for their function and
expression in the brain (ALDOA, DOC2A, HIRIP3, MAPK3, MAZ,
PPP4C, SEZ6L2 and TAOK2). None of them showed a significant
association with ASD at the exception of SEZ6L2 for which a
suggestive association was detected [15], but not confirmed [16].
Smaller deletions at 16p11.2 were identified in individuals with
ASD narrowing the critical region and including the PRRT2 gene
[8,9]. PRRT2 codes for a membrane protein that interacts with
SNAP25, a protein from the synaptic vesicles release machinery
(the SNARE complex). PRRT2 is a compelling candidate gene for
ASD and other psychaitric diseases since a homozygote frameshift
mutation (A217PfsX8) was shown to segregate with non-
syndromic ID in one consanguineous family with 9 affected
individuals [17]. Furthermore numerous heterozygote frameshift,
nonsense and missense PRRT2 mutations (including the recurrent
frameshift A217PfsX8) were identified in individuals and families
with benign infantile seizures (BIS), paroxysmal kinesigenic
dyskinesia (PKD), hemiplegic migraine (HM), or episodic ataxia,
variably associated (e.g. the ICCA syndrome that associates BIS
with PKD) [18–21]. Following these results, we compared the
frequency of deleterious mutations in 431 individuals with ASD
and 186 controls. In addition, we ascertained the genetic
variability of PRRT2 in a sample of 961 individuals from
worldwide populations.
Materials and Methods
Individuals and control samples
Mutation screening of PRRT2 was performed in individuals
with ASD recruited by the PARIS (Paris Autism Research
International Sibpair) study at specialized clinical neuropsychiatric
centers disposed in France and Sweden (Table S1). Diagnosis was
based on comprehensive clinical evaluation by experienced
clinicians using DSM IV-TR criteria; most individuals were
assessed with the Autism Diagnostic Interview-Revised (ADI-R)
and some of them also with the Autism Diagnostic Observation
Scale (ADOS). In Sweden, in some cases, the Diagnostic Interview
for Social and Communication Disorders (DISCO-10) was used
instead of the ADI-R. Cases were included only after a thorough
clinical evaluation, including psychiatric and neuropsychological
examination, standard karyotyping, and fragile-X testing, as well
as brain imaging and EEG whenever possible. For comparison
between cases and controls, only individuals from European
descent were considered (Table S2). The Human Genome
Diversity Panel (HGDP) is a collection of 961 individuals from
worldwide populations [22]. This study was approved by the local
Institutional Review Board (IRB). The local IRB are the Comite´s
de Protection des Personnes Iˆle-de-France VI Sis Hoˆpital Pitie´-
Salpeˆtrie`re 75013 PARIS for France and the Sahlgrenska
Academy Ethics committee, University of Gothenburg for
Sweden. For all probands written inform consent was signed by
the individuals or parents or the legal representative.
Mutation screening of PRRT2
We obtained DNA of 431 unrelated individuals with ASD, 180
controls and 961 individuals without known clinical status from
the Human Genome Diversity Panel (HGDP) from blood
leukocytes or B-lymphoblastoid cell lines, and was extracted with
phenol-chloroform (Table S1, S2). All coding exons of PRRT2
were screened by direct sequencing of the PCR products (Table
S3). The 3 coding exons of PRRT2 (NP_660282.2) and one
supplementary exon present in the splicing isoforms (Q7Z6L0-1,
Q7Z6L0-2, Q7Z6L0-3) were sequenced. For the amplicon of exon
2, that contains the frameshift mutation A217PfsX8, we screened
an additional sample of 295 individuals with ASD and 92 controls.
For all exons, the amplification of 20 ng of DNA template was
performed using a standard PCR protocol with the FastStart Taq
polymerase (Roche): 95uC for 15 min, followed by 35 cycles of
95uC for 30 s, 55 to 64uC (depending on the Tm) for 30 s, 72uC
for 30 s to 1 min (depending on the product size), with a final cycle
at 72uC for 10 min. Direct sequencing of the PCR products was
performed using the BigDye Terminator Cycle V3.1 Sequencing
Kit, and an ABI PRISM genetic analyzer (Applied Biosystems).
For all nonsynonymous variations, the genotype was confirmed by
sequencing an independent PCR product. Because of the low
quantity of DNA for 3 individuals with ASD, we used whole
genome amplification (WGA), using two commercially available
Multiple Displacement Amplification kits. For the GenomiPhi
DNA Amplification Kit (Amersham Pharmacia, Uppsala, Swe-
den), 25 ng of genomic DNA (in 2.5 ml) were mixed with 22.5 ml of
Figure 1. PRRT2 coding variants identified in this study. Schematic diagram of the PRRT2 gene and of the three PRRT2 protein isoforms.
Mutation identified in this study are indicated in green (controls and HGDP), orange (controls, HGDP, and patients) and red (patients only).
doi:10.1371/journal.pone.0088600.g001
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GenomiPhi sample buffer. For the Repli-G Whole Genome
Amplification kit (Qiagen Sciences Inc. Germantown, MD), 25 ng
of genomic material were diluted in TE to a final volume of 2.5 ml.
For comparison with the exome variant server, we verified that the
coverage of the PRRT2 exons was satisfactory (92% of the coding
region had a coverage .20; Figure S1).
Statistical analyses and software
The significance of differences in PRRT2 variants in individuals
and controls was determined by a two-sided Fisher’s exact test on a
two-by-two contingency table. PolyPhen-2 (http://psort.hgc.jp)
and PSORT (http://genetics.bwh.harvard.edu/pph2) were used
to predict the functional impact of amino acid substitutions and
trans-membrane segments, respectively. To estimate the selective
pressure on PRRT2 in different populations (pN/pS), the number
of synonymous SNPs or nonsynonymous SNPs was divided by the
total number of synonymous or nonsynonymous positions in
PRRT2. The number of synonymous and nonsynonymous sites of
PRRT2 were calculated by DnaSP v5 [23].
Results
We sequenced all coding exons of PRRT2 in a large cohort of
1578 individuals including 431 individuals with ASD, 186 controls
and 961 individuals from the HGDP [22]. None of the patients
tested were deleted or duplicated for the 16p11.2 locus. Overall,
we identified 24 nonsynonymous variants, 1 frameshift A217PfsX8
and 1 in-frame deletion of 6 bp (Del 361A-362P) (Table 1,
Figure 1, Table S4 and S5). Among those, 18 were not reported
before (S5N, P18T, P48R, S115K, P140A, T151N, P154S,
E180K, A214P, P215T, G241S, S249P, G258E, G258R,
A272V, R311Q, p.A361_P362del), 1 (A217PfsX8) was repeatedly
found in individuals with BIS, PDK and/or HM as well as in
unaffected carriers, and 7 (E23K, P45S, P138A, D147H, P215R,
P216L, R217Q) were previously observed in the general
population (listed in Exome Variant Server, dbSNP or in the
1000 genomes project, Table S6). After stratification for European
ancestry, we did not observe significant enrichment of coding
sequence variants in the patient sample compared with controls
(Table 1). This absence of enrichment was also observed when
only variants predicted as deleterious were taken into account.
In the patient sample, we were able to ascertain the inheritance
of the variants for 10 families and found that all mutations were
inherited. Interestingly, the majority of the mutations were
inherited from the mother (9/10; P= 0.012). In two individuals
with ASD from sub-Saharan African origin, a 6 bp in-frame
deletion (p.A361_P362del) was identified. The variant was
transmitted by unaffected mothers and never observed in any
individuals from our study and from other PRRT2 mutation
screening or in the 1000 genomes (.2000 controls). The genomes
of these two individuals were investigated using the Illumina 1M
Duo SNP array. Using Identity by state (IBS) analysis, we showed
that these two individuals were not relatives (Table S7), but were
clustered with individuals from South Africa and Kenya (Fig. S2).
This PRRT2 deletion of 2 conserved amino acids occurs in a
predicted transmembrane domain of a specific isoform of PRRT2
(Figure 1). In silico prediction using the PSORT software suggests
however that the deletion does not disrupt the transmembrane
domain of this isoform.
In the control sample, we identified one individual carrying the
frameshift mutation A217PfsX8 already described as causing
autosomal dominant ICCA, BIS, PKD, HM or epilepsy) [18–21].
This control individual had no history of psychiatric and
neurological disorders. To further explore the prevalence of
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A217PfsX8, we screened an additional sample of 295 individuals
with ASD and 92 controls. Overall, A217PfsX8 was observed only
in the control described above and not detected in any of the other
277 controls, 726 individuals with ASD and in any of the 961
individuals from the HGDP.
We used a panel of DNA from individuals originated from
worldwide populations (Figure 2, Table S4 and S5). We could
identify 21 nonsynonymous PRRT2 variants and trace the possible
origin of them. For example, the predicted damaging P140A is a
relatively frequent polymorphism present in Asia (7%), Oceania
(5%), in Native American (7%), but more rare in Europe (allele
frequency ,1%). The A214P variant was observed in Asian (allele
frequency ,1%) and Native American populations. The P216L
was observed in North Africa (allele frequency 1,7%), Europe
(,1%) and Asia (,1%). Interestingly, we observed a higher ratio
of nonsynonymous vs synonymous variants in Asia compared with
Africa. In Asia, we found only 1 synonymous variant (E127E)
carried by a single individual (allelic frequency of synonymous
variants: 1/878= 0.12%) and 15 nonsynonymous variants (S5N,
P18T, P48R, P140A, D147H, T151N, P154S, A214P, P215T,
P215R, P216L, G258E, A272V, R311Q) carried by 78 individuals
(allelic frequency of nonsynonymous variants: 86/878= 9,8%). In
contrast, in Africa, we found 3 synonymous variants (P215P,
L251L, C276C) carried by 7 individuals (allelic frequency of
synonymous variants: 8/216= 3.7%) and only 1 nonsynonymous
variant (P45S) carried by 2 individuals (allelic frequency of
nonsynonymous variants: 2/216= 0.92%).
To evaluate selective constraints on PRRT2 in the different
populations, we estimated pN/pS the ratio of nonsynonymous
(pN) to synonymous polymorphism (pS) in each population sample
(Table 2). Usually, most nonsynonymous changes would be
expected to be eliminated by purifying selection, but under
certain conditions positive Darwinian selection may lead to their
retention [24]. Investigating the number of synonymous and non-
synonymous substitutions therefore provides information about
the degree of selection operating on a gene. A pN/pS ratio greater
Figure 2. PRRT2 variants identified in individuals from worldwide populations. A total of 961 individuals from the human genome diversity
panel (HGDP) were sequenced for all PRRT2 exons. The diameter of each circle is proportional to the number of individuals who were sequenced for
PRRT2.
doi:10.1371/journal.pone.0088600.g002
Table 2. Synonymous and nonsynonymous variations of PRRT2 in worldwide populations.
Ethnic
Nonsynonymous
variants
Synonymous
variants
pN (nonsynonymous variants/
nonsynonymous sites)a
pS (synonymous variants/
synonymous sites)a pN/pS
EVS Europe (N = 4300) 14 3 0.021 0.013 1.62
EVS African-American
(N = 2012)
6 8 0.009 0.035 0.26
HGDP Asia (N = 439) 14 1 0.021 0.004 4.85
HGDP Africa (N = 108) 1 2 0.001 0.009 0.17
HGDP Europe (N = 159) 4 0 0.006 0.000 .1.5b
aNumber of nonsynonymous and synonymous sites for PRRT2 are 668.5 and 231.5, respectively.
bFor the calculation of the pN/pS for Europe, the value of pS was set to 0.004 (the minimum of 1 synonymous variant observed in 159 individuals).
doi:10.1371/journal.pone.0088600.t002
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than one implies positive Darwinian selection; less than one
implies purifying (stabilizing) selection; and a ratio of one indicates
neutral (i.e. no) selection [25]. The calculation of the pN/pS ratio
in the different populations revealed sign of positive Darwinian
selective pressure on PRRT2 in Asia (pN/pS=4.85) compared to
Africa (pN/pS= 0.17; Fischer exact test P = 0.000087). For
Europe (pN/pS.1.5), there was a trend for higher nonsynon-
ymous mutations compared to Africa (Fischer exact test P= 0.057).
We therefore tested if this difference was also observed between
American European and American African populations available
in the Exome Variant Server database (Table 2). Using this large
dataset of 4300 individuals from European ancestry and 2012
individuals from African ancestry, we could confirm that there was
a significant increase of nonsynonymous variants in Europe (pN/
pS=1.62) compared to Africa (pN/pS= 0.26) (Fischer exact test
P = 0.00035). Finally, we observed a trend for higher frequency of
nonsynonymous variants in Asia compared to Europe (Fischer
exact test P= 0.084). As expected, there was no difference between
populations from the HGDP and those from EVS (Africa HGDP
vs Africa EVS P= 0.67; Europe HGDP vs Europe EVS P= 1). In
order to test whether this difference in selective pressure was
specific to PRRT2, we used the data from EVS and extended our
pN/pS calculation to all genes included in the 16p11.2 deletion
(Figure 3; Table S8). We observed that the majority of the genes
had a very similar pN/pS in Europe and Africa. Only C16orf92
showed a higher pN/pS in Africa compared to Europe. In
contrast, ASPHD1, YPEL3, MAPK3 and PRRT2 showed a
higher pN/pS in Europe compared to Africa. However, PRRT2
was the only gene with a pN/pS significantly different in Europe
and Africa after correction for multiple testing.
During the screening of the recurrent frameshift mutation
‘A217PfsX8’, we used whole genome amplified DNA for three
individuals with ASD. Strikingly, we observed the A217PfsX8
mutation in these three samples for which the DNA was amplified
using rolling circle amplification protocol (Genomiph from
GEHealthcare) (Figure 4). We obtained the native DNA from
these three individuals and found that they were actually not
carrying the A217PfsX8 mutation. We then re-amplified the
native DNA from these three individuals using another RCA
protocol (REPLI-g Mini method from QIAGEN). After direct
sequencing of the PCR products, the A217PfsX8 frameshift
mutation was again present. Based on these results, we strongly
advise that PRRT2 mutation screening should not be performed
on DNA previously amplified through RCA.
Discussion
Both deletions and duplications at 16p11.2 increase the risk for
ASD, but the genes and the mechanisms involved remain largely
unknown. Whereas several other strong candidate genes including
the KCTD13 gene are located within the deletion and can be
considered possible driver(s) as well [26], PRRT2 was indeed a very
compelling candidate. Homozygous PRRT2 mutations were
associated with clinical features also observed in a subset of
individuals with ASD such as intellectual disability and epilepsy.
PRRT2 encodes a putative membrane protein, localized at the
synaptic membrane and interacting with SNAP25, a member of
the SNARE protein complex involved in the release of synaptic
vesicles. Our study was designed to identify new coding variants of
PRRT2 in a relatively large sample of individuals with ASD and to
ascertain the genetic variability of the gene in worldwide
populations.
We could not find any deleterious PRRT2 mutation enrichment
in individuals with ASD compared with controls. None of the
patients tested were deleted or duplicated for the 16p11.2 locus. In
addition, we did not find causative PRRT2 mutations previously
associated with neurological diseases such as PDK, ICCA, epilepsy
or migraine in our cohort of patients. We observed a significant
enrichment of maternally transmitted mutations in the individuals
with ASD (9/10 transmitted by the mother). However, this
apparent disequilibrium might have occurred by chance since to
our knowledge, no transmission disequilibrium was reported for
Figure 3. Genetic variability in Europe and Africa for all genes located within the 16p11.2 deletion. A. Nonsynonymous mutations per
nonsynonymous sites (pN) and synonymous mutations per synonymous sites (pS) were estimated using the data from 4300 individuals from
European ancestry and 2012 individuals from African ancestry available at the Exome Variant Server (http://evs.gs.washington.edu/EVS/). The
horizontal lanes correspond to the means of pN and pS for the 27 genes. Difference of pN/pS between Europe and Africa were calculated using a 2-
tailed Fisher exact test and the 2Log10 P value is indicated. B. Plot of the 2Log10 P values obtained for the difference between the pN/pS ratio in
Africa and in Europe in relation the ratio (Europe pN/pS)/(Africa pN/pS).
doi:10.1371/journal.pone.0088600.g003
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PRRT2 mutations in other neurological diseases. Taken together,
these results indicate that mutations in PRRT2 are not a frequent
cause of autism. Our study cannot however exclude that, in
individuals with 16p11.2 deletions, haploinsufficiency of PRRT2
could increase the risk of ASD.
Secondly, we detected the presence of the deleterious truncating
mutation A217PfsX8 in a control (of note the DNA of this
individual was not whole genome amplified). This man had no
psychiatric diseases and, to his knowledge, no history of any
psychiatric disorders in his first and second degree relatives
(parents and grand parents). This individual had no diagnostic for
migraine and epilepsy, but was unavailable for further clinical
explorations in order to detect mild signs of neurological problems.
Similar incomplete penetrance of the A217PfsX8 mutation was
Figure 4. Chromatograms of the PRRT2 A217PfsX8 mutation before and after whole genome amplification. The chromatograms of
PRRT2 sequence before (Native DNA) and after whole genome amplification of the DNA from three independent patients using two different
protocols GenomiPhi DNA Amplification Kit (WGA-1) or Repli-G Whole Genome Amplification kit (WGA-2). The mutation was not present in the native
DNA, but was detected after whole genome amplification.
doi:10.1371/journal.pone.0088600.g004
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observed in carriers from families with ICCA syndrome [21].
Based on the literature, the penetrance of the A217PfsX8
mutation was estimated to 94% [27]. It remains unknown if
additional genetic variants could act as suppressors in the
unaffected individuals carrying the A217PfsX8 mutation.
Thirdly, we ascertained the genetic variability of PRRT2 in
worldwide populations. We identified 21 novel nonsynonymous
variants including 17 never reported before and 4 already listed in
the nucleotide variant database (Table S6). Despite the relatively
large number of chromosomes tested and the population diversity,
we did not observe any truncating mutations. Most of the
nonsynonymous variants are restricted to one population (D147H,
P154S, E180K, P215R, G241S, G258E and G258R) or to closely
related populations (A214P and P216L). One variant P140A was
frequently observed in different populations with a shared genetic
origin (Asia, Native American and Oceania). Overall, the low rate
(,1%) of nonsynonymous mutation indicates that PRRT2 is under
strong selective pressure. Nevertheless, our results also revealed a
heterogenous pattern of selective pressure acting on PRRT2 in
human populations. The low pN/pS ratio in Africa indicates
PRRT2 is under the usual purifying selection (as for the majority of
the genome), whereas the pN/pS ratio in Asia and Europe is
higher than expected and consistent with positive Darwinian
selection [28]. To date, we have no explanation for this
observation. Within the 16p11.2 deletion, PRRT2 seems to be
the gene with the higher difference of selective pressure between
Europe and Africa, but addition samples should be screened to
ascertain if this difference is specific to PRRT2 or is also true for
other genes within the deletion. Considering this heterogeneous
pattern of selective pressure, it would be interesting to see if there is
a higher prevalence of PRRT2 related disease in Asia and Europe
compared to Africa. It would also be interesting to explore the
genetic diversity of the binding partners of PRRT2 in order to
decipher whether this lower selective pressure is restricted to
PRRT2 or to other members of the same pathway.
Finally, we showed that whole genome amplification using
multiple displacement amplification technology such as Genomi-
Phi and Repli-G could lead to the appearance of the A217PfsX8
mutation. The genomic region surrounding the mutation is made
of 4 guanines and 9 cytosines and seems therefore to be at risk for
mutation both in vivo and in vitro. For this reason, we strongly
suggest that PRRT2 mutation screening should be restricted to
native DNA and validate using Sanger sequencing. Interestingly,
in the last release of the Exome Variant Server database, at the
same location of the A217PfsX8 mutation (hg19, chr16:
29825015), 10% of the PRRT2 allele contains an additional C
(allele A1 in EVS) and 10% have a deletion of a C (allele A2 in
EVS), but with very low average sample read depth (N=10).
Given the very high penetrance of the A217PfsX8 mutation in
PRRT2-related diseases, it is impossible that 20% of the PRRT2
alleles carry a frame shift mutation at this position. Especially,
since we found the A217PfsX8 mutation in only 1 individual out of
1990 (Allelic frequency = 0.025%). This high frequency of
A217PfsX8 mutation in EVS could be related to the DNA
amplification step required for whole exome sequencing. Studying
the mechanism leading to the A217PfsX8 mutation was beyond
the scope of our study, but our observation that a DNA
amplification step through RCA could introduce this additional
C/G might help in understanding the mechanism leading to
A217PfsX8 mutation.
In summary, our study indicates that PRRT2 mutations do not
play a major role in the susceptibility to ASD and confirm that
truncating mutations of PRRT2 are not fully penetrant. We also
provide an ascertainment of the genetic diversity of PRRT2 in
worldwide populations as well as important indication on the
pitfalls for the mutation screening. All together, these results
should help researchers and clinicians to better investigate the role
of PRRT2 in human diseases.
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